Hypothesis of interference to superinfection between bovine spastic paresis and bovine spongiform encephalopathy; suggestions for experimentation, theoretical and practical interest

Medical Hypotheses

Volumn 62, Issue 3, 2004, Pages 346-353

  Ledoux, Jean Marie ^a  

^a DVM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; COPPER; GLATIRAMER; GLUTAMIC ACID; LITHIUM; MANGANESE; PRION PROTEIN; TRYPTOPHAN; TYROSINE; VACCINE;

BOVINE SPONGIFORM ENCEPHALOPATHY; CATTLE DISEASE; DEGENERATIVE DISEASE; EXPERIMENTAL ANIMAL; EXPERIMENTATION; INCUBATION TIME; INOCULATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RETROVIRUS; REVIEW; SCRAPIE; SPASTIC PARESIS; SUPERINFECTION; VIRULENCE; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALIA; BOS TAURUS; BOVINAE;

EID: 1642351626     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.019     Document Type: Article

References (40)

1. Manuelidis L. Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc Natl Acad Sci USA 1998;95:2520-5.
2. Arnault G. Parésie spastique bovine et encéphalopathies spongiformes subaiguës: comparaisons, hypothèses, suggestions d'expèrimentation. Bull Soc Vét Prat France 1991;75:339-53.
3. Manuelidis L, Lu ZY. Virus-like interference in the latency and prevention of Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 2003;100:5360-5.
4. Manuelidis L. Transmissible encephalopathies: speculations and realities. Viral Immunol 2003;16:123-39.
5. Baker CA, Martin D, Manuelidis L. Microglia from Creutzfeldt-Jakob disease-infected brains are infectious and show specific mRNA activation profiles. J Virol 2002;76:10905-13.
6. Chiesa R, Harris DA. Prion diseases: what is the neurotoxic molecule? Neurobiol Dis 2001;8:743-63.
7. Race R, Meade-White K, Raines A, Raymond GJ, Caughey B, Chesebro B. Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation of infectivity during four passages. J Infect Dis 2002;186(Suppl 2):S166-170.
8. Thackray AM, Klein MA, Bujdoso R. Subclinical prion disease induced by oral inoculation. J Virol 2003;77: 7991-8.
9. Lasmézas CI, Deslys J-P, Robain O, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997;275:402-5.
10. Sc deposition and vacuolation in the brains of scrapie and BSE experimentally affected goats. J Gen Virol 2001;82:267-73.
11. Fraser JR. What is the basis of transmissible spongiform encephalopathy induced neurodegeneration and can it be repaired? Neuropathol Appl Neurobiol 2002;28:1-11.
12. Hill AF, Antoniou M, Collinge J. Protease-resistant prion protein produced in vitro lacks detectable infectivity. J Gen Virol 1999;80:11-4.
13. Manuelidis L, Sklaviadis T, Akowitz A, Fritch W. Viral particles are required for infection in neurodegenerative Creutzfeldt-Jakob disease. Proc Natl Acad Sci USA 1995;92:5124-8.
14. Gabus C, Derrington E, Leblanc P, et al. The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCp7 of HIV-1. J Biol Chem 2001;276:19301-9.
15. Adler V, Zeiler B, Kryukov V, Kascsak R, Rubenstein R, Grossman A. Small, highly structured RNAs participate in the conversion of human recombinant PrP (Sen) to PrP (Res) In vitro. J Mol Biol 2003;332:47-57.
16. Ossa JE, Machado G, Giraldo MA, McEven JG. Prion plaques: molecular tumors. A hypothesis on the etiopathogenesis of prion diseases. Med Hypotheses 1995;44:124-6.
17. Manuelidis L, Lu ZY. Attenuated Creutzfeldt-Jakob disease agents can hide more virulent infections. Neurosci Lett 2000;293:163-6.
18. Manuelidis EE, Manuelidis L. A transmissible Creutzfeldt-Jakob disease-like agent is prevalent in the human population. Proc Natl Acad Sci USA 1993;90:7724-8.
19. Corbin A, Sitbon M. Interférence à la surinfection: un mécanisme non immunitaire de vaccination contre les maladies rétrovirales. m/s 1993;9:967-70.
20. Heard J-M, Rodrigues P, Salaün C. Une collaboration étroite et efficace: les enveloppes rétrovirales et leurs récepteurs cellulaires. m/s 1999;15:994-8.
21. Westarp ME, Westphal KP, Clausen J, et al. Retroviral interference with neuronotrophic signalling in human motor neuron disease? Clin Physiol Biochem 1993;10:1-7.
22. Münk C, Thomsen S, Stocking C, Löhler J. Murine leukemia virus recombinants that use phosphate transporters for cell entry induce similar spongiform encephalomyelopathies in newborn mice. Virology 1998;252:318-23.
23. Rasko JEJ, Battini J-L, Gottschalk RJ, Mazo I, Miller AD. The RD114/simian type D retrovirus receptor is a neutral amino acid transporter. Proc Natl Acad Sci USA 1999;96:2129-34.
24. Summers C, Neill W, Dewar P, et al. Systemic immune responses following infection with Jaagsiekte sheep retrovirus and in the terminal stages of ovine pulmonary adenocarcinoma. J Gen Virol 2002;83:1753-7.
25. DeMartini JC, Carlson JO, Leroux C, Spencer T, Palmarini M. Endogenous retroviruses related to Jaagsiekte sheep retrovirus. Curr Top Microbiol Immunol 2003;275:117-37.
26. Spencer TE, Mura M, Gray CA, Griebel PJ, Palmarini M. Receptor usage and fetal expression of ovine endogenous betaretroviruses: implications for coevolution of endogenous and exogenous retroviruses. J Virol 2003;77:749-53.
27. Alberti A, Murgia C, Liu SL, et al. Envelope-induced cell transformation by ovine betaretroviruses. J Virol 2002;76:5387-94.
28. Danilkovitch-Miagkova A, Duh FM, Kuzmin I, et al. Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by Jaagsiekte sheep retrovirus. Proc Natl Acad Sci USA 2003;100:4580-5.
29. Pérez M, Rojo AI, Wandosell F, Diaz-Nido J, Avila J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthetase kinase 3. Biochem J 2003;372:129-36.
30. Ledoux J-M. La parésie spastique bovine est-elle une maladie transmissible? Bull Soc Vét Prat France 1996;80: 453-67.
31. Ledoux J-M. Bovine spastic paresis: etiological hypotheses. Med Hypotheses 2001;57:573-9.
32. Ledoux J-M. Features of the comparative pharmacokinetics of lithium; a potential application of its use in livestock farming. Med Hypotheses 2003;61:278-81.
33. Everall IP, Bell C, Mallory M, et al. Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 2002;21:493-501.
34. Harris DA, Falls DL, Johnson FA, Fischbach GD. A prion-like protein from chicken brain copurifies with an acetylcholine receptor-inducing activity. Proc Natl Acad Sci USA 1991;88:7664-8.
35. Bucheton A. The relationship between the flamenco gene and gypsy in Drosophila: how to tame a retrovirus. Trends Genet 1995;11:349-53.
36. Deleault NR, Lucassen RW, Supattapone S. RNA molecules stimulate prion protein conversion. Nature 2003;425: 717-20.
37. Stahl N, Borchelt DR, Prusiner SB. Differential release of cellular and scrapie prion proteins from cellular membranes by phosphatidylinositol-specific phospholipase C. Biochemistry 1990;29:5405-12.
38. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 2003;423:435-9.
39. Goudsmit J, Rohwer RG, Silbergeld EK, Gajdusek DC. Hypersensitivity to central serotonin receptor activation in scrapie-infected hamsters and the effect of serotonergic drugs on scrapie symptoms. Brain Res 1981;220:372-7.
40. Simpson D, Noble S, Perry C. Glatiramer acetate. A review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002;16:825-50.